Overview

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent over a range of advanced and/or metastatic solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
GI Innovation, Inc.